{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:14:48Z","timestamp":1788077688606,"version":"build-2784847793"},"reference-count":28,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background: In type 2 diabetes mellitus with obesity, both glycemic control and weight reduction are required; enhancing endogenous GLP-1 signaling has clinical value; TGR5 is an upstream target and the curcumin family has attracted attention but mechanistic evidence is scattered. Objectives: To evaluate, at structural and system levels, the mechanistic feasibility of the \u201ccurcumin\u2013TGR5\u2013GLP-1 axis\u201d and to generate a prioritized ranking of candidates. Methods: Four human TGR5\u2013Gs structures were used for redocking and Vina\/GNINA consensus docking; based on the best poses, 200 ns\u00d73 molecular dynamics (n=3) and MM-PBSA (100\u2013200 ns) were performed; a GLP-1 module and a T2DM?obesity network were constructed to conduct enrichment, proximity and randomization tests; receptor reachability was assessed by integrating ADMET and Rdirect evidence was integrated according to preregistered weights. Results: Redocking validated reliability (9GYO pass rate 85.00%, RMSD = 0.86 A; 7CFN 75.00%, 1.17 \u00c5; 7XTQ 65.00%, 1.39 \u00c5). The consensus ranking was INT-777 &gt; tetrahydrocurcumin &gt; curcumin; demethoxycurcumin and bisdemethoxycurcumin tied, followed by curcumin-glucuronide and curcumin-sulfate. Molecular dynamics showed Hyd-W237\/Hyd-F96 occupancy about 55%\u201379%, late-phase (100\u2013200 ns) Hyd-L71 about 70%\u201381%; Hbond-Y240 about 28%\u201336%, Hbond-N93 in the late phase (100\u2013200 ns) about 30%\u201336%, with key interactions stabilizing at 70\u2013100 ns. MM-PBSA indicated INT-777 ?28.94 kcal\/mol, tetrahydrocurcumin ?24.63, curcumin ?18.72. Network statistics suggested closer inter-set adjacency: ?_obs = ?0.53 (Z = ?2.79, P_perm = 0.006), s_obs = ?0.58 (Z = ?2.76, P_perm = 0.008); enrichment was dominated by cAMP and G?s-related pathways (q &lt; 0.05). R_direct classified INT-777 = 0.78 and tetrahydrocurcumin = 0.64 as favorable, with all others &lt; 0.50. Conclusion: Curcumin modulating the GLP-1 pathway via TGR5 is mechanistically feasible; tetrahydrocurcumin ranks superior across structural, system and reachability dimensions and is a prioritized candidate for experimental validation; conclusions are limited to binding feasibility, mechanistic indications and prioritization.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.9.243.1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:11:34Z","timestamp":1782630694000},"source":"Crossref","is-referenced-by-count":0,"title":["Network pharmacology combined with molecular docking to investigate the potential role of curcumin targeting TGR5 to modulate the GLP-1 pathway in T2DM with obesity"],"prefix":"10.36721","author":[{"given":"Chengyi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes\u20142025. Diabetes Care, 48(Suppl 1): S167-S180.","DOI":"10.2337\/dc25-S008"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bertoncini-Silva C, Vlad A, Ricciarelli R, Giacomo Fassini P, Suen VMM and Zingg JM (2024). Enhancing the bioavailability and bioactivity of curcumin for disease prevention and treatment. Antioxidants (Basel), 13(3): 331.","DOI":"10.3390\/antiox13030331"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, Gribble FM and Reimann F (2015). Bile acids trigger GLP-1 release predominantly by accessing basolaterally located GPBAR1 (TGR5) on L-cells. Endocrinology, 156(11): 3961-3970.","DOI":"10.1210\/en.2015-1321"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chen G, Wang X, Ge Y, Ma L, Chen Q, Liu H, Du Y, Ye RD, Hu H and Ren R (2020). Cryo-EM structure of activated bile acids receptor TGR5 in complex with stimulatory G protein. Signal Transduct Target Ther., 5(1): 142.","DOI":"10.1038\/s41392-020-00262-z"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G and Rossing P (2022). Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11): 2753-2786.","DOI":"10.2337\/dci22-0034"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF and Forli S (2021). AutoDock Vina 1.2.0: New docking methods, expanded force field and Python bindings. J Chem Inf Model., 61(8): 3891-3898.","DOI":"10.1021\/acs.jcim.1c00203"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Fleishman JS and Kumar S (2024). Bile acid metabolism and signaling in health and disease: Molecular mechanisms and therapeutic targets. Signal Transduct Target Ther., 9: 97.","DOI":"10.1038\/s41392-024-01811-6"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gan X, Shu Z, Wang X, Yan D, Li J, Ofaim S, Albert R, Li X, Liu B, Zhou X and Barabasi AL (2023). Network medicine framework reveals generic herb-symptom effectiveness of traditional Chinese medicine. Sci Adv., 9(43): eadh0215.","DOI":"10.1126\/sciadv.adh0215"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Gonzalez Y, Mojica-Flores R, Moreno-Labrador D, Pecchio M, Rao KJ, Ahumedo-Monterrosa M, Fernandez PL, Larionov OV and Lakey-Beitia J (2023). Tetrahydrocurcumin derivatives enhanced the anti-inflammatory activity of curcumin: Synthesis, biological evaluation and structure\u2013activity relationship analysis. Molecules, 28(23): 7787.","DOI":"10.3390\/molecules28237787"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"He Y, Chen X, Li Y, Liang Y, Hong T, Yang J, Cao Z, Mai H, Yao J, Zhang T and Wu K (2024). Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota\u2013dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: A randomized controlled trial. Am J Clin Nutr., 120(1): 66-79.","DOI":"10.1016\/j.ajcnut.2024.05.017"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Jin W, Zheng M, Chen Y and Xiong H (2024). Update on the development of TGR5 agonists for human diseases. Eur J Med Chem., 271: 116462.","DOI":"10.1016\/j.ejmech.2024.116462"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Leidner F, Kurt Yilmaz N and Schiffer CA (2019). Target-specific prediction of ligand affinity with structure-based interaction fingerprints. J Chem Inf Model., 59(9): 3679-3691.","DOI":"10.1021\/acs.jcim.9b00457"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lok KH, Wareham NJ, Nair RS, How CW and Chuah L-H (2022). Revisiting the concept of incretin and enteroendocrine L-cells as type 2 diabetes mellitus treatment. Pharmacol Res., 180: 106237.","DOI":"10.1016\/j.phrs.2022.106237"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ma L, Yang F, Wu X, Mao C, Guo L, Miao T, Zang SK, Jiang X, Shen DD, Wei T and Zhou H (2022). Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity. Proc Natl Acad Sci USA, 119(29): e2117054119.","DOI":"10.1073\/pnas.2117054119"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Moon DO (2025). Structure-Based Insights into TGR5 Activation by natural compounds: Therapeutic implications and emerging strategies for obesity management. Biomedicines, 13(10): 2405.","DOI":"10.3390\/biomedicines13102405"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Muller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF and Holst JJ (2019). Glucagon-like peptide 1 (GLP-1). Mol Metab., 30: 72-130.","DOI":"10.1016\/j.molmet.2019.09.010"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Panossian A (2025). Trends and pitfalls in the progress of network pharmacology research on natural products. Pharmaceuticals (Basel), 18(4): 538.","DOI":"10.3390\/ph18040538"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pinero J, Ramirez-Anguita JM, Sauch-Pitarch J, Ronzano F, Centeno E, Sanz F and Furlong LI (2020). The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res., 48(D1): D845-D855.","DOI":"10.1093\/nar\/gkz1021"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C, Gluckman TJ, Stucky N and Emanuel EJ (2025). Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open, 8(1): e2457349.","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Tian F, Chen T, Xu W, Fan Y, Feng X, Huang Q and Chen J (2023). Curcumin compensates GLP-1 deficiency via the microbiota-bile acids axis and modulation in functional crosstalk between TGR5 and FXR in ob\/ob mice. Mol Nutr Food Res., 67(22): e2300195.","DOI":"10.1002\/mnfr.202300195"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Torrens-Fontanals M, Stepniewski TM, Aranda-Garcia D, Morales-Pastor A, Medel-Lacruz B and Selent J (2020). How do molecular dynamics data complement static structural data of GPCRs. Int J Mol Sci., 21(16): 5933.","DOI":"10.3390\/ijms21165933"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Tomek J and Zaccolo M (2023). Compartmentalized cAMP signalling and control of cardiac rhythm. Philos Trans R Soc Lond B Biol Sci., 378(1879): 20220172.","DOI":"10.1098\/rstb.2022.0172"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Urosevic M, Nikolic L, Gajic I, Nikolic V, Dinic A and Miljkovic V (2022). Curcumin: Biological activities and modern pharmaceutical forms. Antibiotics (Basel), 11(2): 135.","DOI":"10.3390\/antibiotics11020135"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R, Xu X and Li T (2022). Signaling pathways in obesity: Mechanisms and therapeutic interventions. Signal Transduct Target Ther., 7(1): 298.","DOI":"10.1038\/s41392-022-01149-x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yang F, Mao C, Guo L, Lin J, Ming Q, Xiao P, Wu X, Shen Q, Guo S, Shen DD and Lu R (2020). Structural basis of GPBAR activation and bile acid recognition. Nature, 587(7834): 499-504.","DOI":"10.1038\/s41586-020-2569-1"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Yadav R and Zaccolo M (2025). GPCR signaling via cAMP nanodomains. Biochem J., 482(10): 519-533.","DOI":"10.1042\/BCJ20253088"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zheng L, Meng J, Jiang K, Lan H, Wang Z, Lin M, Li W, Guo H, Wei Y and Mu Y (2022). Improving protein\u2013ligand docking and screening accuracies by incorporating a scoring function correction term. Brief Bioinform., 23(3): bbac051.","DOI":"10.1093\/bib\/bbac051"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C and Gao J (2024). Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct Target Ther., 9(1): 234.","DOI":"10.1038\/s41392-024-01931-z"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T07:29:47Z","timestamp":1788074987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":28,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.9.243.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}